Health Condition 1: I509- Heart failure, unspecified
Conditions
Interventions
Intervention1: Early introduction of ACE (angiotensin converting enzyme) inhibitor - enalapril: Furosemide at dose of 2 mg/kg/day q12hr through oral route
Enalapril at dose of 0.1 mg/kg/day q24hr through oral route started within 24 hours of starting furosemide
The drug Enalapril and Furosemide which will be used in intervention group are established a
Sponsors
All India Institute of Medical Sciences, Patna
Eligibility
Inclusion criteria
Inclusion criteria: All children aged 1 month to 10 years of either sex with medium sized VSD (diagnosed by 2D echo) presenting with congestive heart failure
Exclusion criteria
Exclusion criteria: i. Patients already on enalapril ii. Patients who have already undergone surgical correction of VSD iii. Patients with small and large sized VSD iv. Patients with renal dysfunction or hyperkalemia v. Patients with cardiogenic shock
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Resolution of respiratory distress (based on respiratory rate (/min) (resolution of tachypnea), retractions – subcostal/intercostal/suprasternal, nasal flaring and grunting).Timepoint: 1 week and 1 month after starting intervention | — |
Secondary
| Measure | Time frame |
|---|---|
| i. Resolution of signs of heart failure – regression of liver size below right costal margin (in cm) and difference in liver span (in cm) ii. Number of admissions and total days of admission iii. Recurrence of respiratory distress – tachypnea or retractions (assess at 1 week and 1 month)Timepoint: 1 week and 1 month after starting intervention | — |
Countries
India
Contacts
Public ContactDr Chandra Raj Datta
All India Institute of Medical Sciences, Patna
Outcome results
None listed